Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview

Area of Science:

• Cellular immunotherapy
• Gene therapy
• Molecular biology

Background:

• Chimeric antigen receptor (CAR) T cell therapy has revolutionized hematologic malignancy treatment.
• Current viral vector-based gene transfer for CAR T cells is expensive and difficult to scale.
• There is a need for cost-effective, scalable nonviral methods for CAR T cell engineering.

Purpose of the Study:

• To evaluate the Sleeping Beauty (SB) transposition system using minicircles (MCs) as a nonviral gene transfer method for CAR T cells.
• To address limitations of traditional plasmid-based SB transposition, such as T cell toxicity and low gene transfer efficiency.

Main Methods:

• Utilized the Sleeping Beauty (SB) transposon system for gene transfer of CAR into T cells.
• Employed minicircles (MCs) as reduced-size DNA vectors to replace conventional plasmids.
• Assessed T cell viability and CAR gene transfer rates following electroporation with MC-based SB vectors.

Main Results:

• Electroporation with two nucleic acids, including the CAR gene and SB transposase, enabled stable CAR transfer.
• Minicircle (MC) vectors significantly reduced T cell toxicity and improved gene transfer efficiency compared to standard plasmids.
• MC-mediated SB CAR transposition facilitated the production of therapeutic doses of CAR T cells.

Conclusions:

• Minicircle (MC)-based Sleeping Beauty (SB) transposition is a promising nonviral platform for CAR T cell engineering.
• This method offers enhanced T cell viability and gene transfer rates, crucial for clinical-grade CAR T cell production.
• MC-mediated SB transposition presents a scalable and cost-effective alternative for widespread CAR T cell therapy.